SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update

About this update from Siga Technologies Inc.

Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. “In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer. “In 2026, we are focused on building on our long-standing track record as a successful partner to the U.S. Government and international governments to secure new procurement contracts and orders that will serve as the foundation of our revenues in the years ahead. Accordingly, in January, we started the year strong and received a $13 million procurement order from a customer in the Asia Pacific region for oral TPOXX.” Summary Financial Results ($ in millions, exceptper share amounts)Three Months EndedDecember 31 Year EndedDecember 31 2025 2024 2025 2024Product sales(1)$2.2 $79.8 $88.0 $133.3Total revenues(2)$3.8 $81.4 $94.6 $138.7Operating (loss)/income(3) (4)($9.5) $57.1 $23.7 $70.0(Loss)/income before income taxes(3)($7.9) $58.6 $30.4 $76.1Net (loss)/income($5.4) $45.7 $23.3 $59.2Diluted (loss)/income per share($0.08) $0.63 $0.32 $0.82 (1) Includes supportive services related to product sales. (2) Includes research and development revenues.(3) Operating (loss)/income excludes, and (Loss)/Income before income taxes includes, other income. Both line items exclude the impact of income taxes.(4) Differences in operating income margin between periods reflect different product mixes in those periods. Key Activities In January 2026, the Company received an order from a country in the Asia Pacific region for $13 million of oral TPOXX® treatment courses. The procurement order is part of a recently signed multi-year contract that includes options for the potential purchase of additional courses. Courses under the $13 million procurement order are expected to be delivered in 2026.During 2025, the Company generated $53 million of oral TPOXX revenues ...

View stock analysis, news, and events for Siga Technologies Inc.